Chicago Equity Partners LLC purchased a new stake in Repligen Corporation (NASDAQ:RGEN) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 29,215 shares of the biotechnology company’s stock, valued at approximately $1,120,000. Chicago Equity Partners LLC owned about 0.08% of Repligen Corporation at the end of the most recent quarter.

Several other large investors have also made changes to their positions in RGEN. Quantbot Technologies LP bought a new stake in Repligen Corporation in the second quarter worth about $120,000. Oppenheimer Asset Management Inc. bought a new stake in Repligen Corporation in the second quarter worth about $123,000. JPMorgan Chase & Co. lifted its stake in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 908 shares during the last quarter. Victory Capital Management Inc. lifted its stake in Repligen Corporation by 17.7% in the second quarter. Victory Capital Management Inc. now owns 4,001 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 601 shares during the last quarter. Finally, Pinebridge Investments L.P. lifted its stake in Repligen Corporation by 1.7% in the second quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 76 shares during the last quarter. 96.47% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “29,215 Shares in Repligen Corporation (RGEN) Purchased by Chicago Equity Partners LLC” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/29215-shares-in-repligen-corporation-rgen-purchased-by-chicago-equity-partners-llc/1706621.html.

Repligen Corporation (RGEN) opened at $32.61 on Thursday. The company has a market cap of $1,417.18, a P/E ratio of 56.09, a PEG ratio of 2.16 and a beta of 1.05. Repligen Corporation has a 1 year low of $28.48 and a 1 year high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last issued its earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.04. The business had revenue of $36.58 million for the quarter, compared to analyst estimates of $35.69 million. Repligen Corporation had a net margin of 16.93% and a return on equity of 7.57%. The company’s quarterly revenue was up 48.2% compared to the same quarter last year. During the same period last year, the company posted $0.08 earnings per share. analysts predict that Repligen Corporation will post 0.6 EPS for the current fiscal year.

Several analysts have issued reports on RGEN shares. TheStreet raised shares of Repligen Corporation from a “c+” rating to a “b-” rating in a research note on Friday, August 11th. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research note on Saturday, August 12th. BidaskClub raised shares of Repligen Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, August 9th. CL King started coverage on shares of Repligen Corporation in a research note on Monday. They issued a “buy” rating and a $41.00 price objective for the company. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $40.00 price objective on shares of Repligen Corporation in a research note on Thursday, October 19th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Repligen Corporation presently has a consensus rating of “Buy” and an average price target of $44.67.

Repligen Corporation Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.